Last reviewed · How we verify

NCT03295487

ToT and Estrogen in Postmenopausal Females

Completed Phase 2, PHASE3 Last updated 25 October 2022
What this trial tests

Phase 2, PHASE3 trial testing TVT-O in Stress Urinary Incontinence in 210 participants. Completed in 30 November 2020.

Timeline
1 March 2017
Primary endpoint
30 November 2020
30 November 2020

Quick facts

Lead sponsorKasr El Aini Hospital
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment210
Start date1 March 2017
Primary completion30 November 2020
Estimated completion30 November 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Kasr El Aini Hospital

Who can join

Adults 49 to 65, female only, with Stress Urinary Incontinence or Postmenopausal Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the subjective and objective outcomes of TVT-O procedure alone versus the same procedure followed by the use of premarin vaginal cream for 3 months in postmenopausal female with genuine stress incontinence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stress Urinary Incontinence

Currently open trials in the same condition.

Other Kasr El Aini Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03295487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing